Cargando…
Bias in progression‐free survival analysis due to intermittent assessment of progression
Cancer clinical trials are routinely designed to assess the effect of treatment on disease progression and death, often in terms of a composite endpoint called progression‐free survival. When progression status is known only at periodic assessment times, the progression time is interval censored, an...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744753/ https://www.ncbi.nlm.nih.gov/pubmed/26011411 http://dx.doi.org/10.1002/sim.6529 |